Preparation method of human macrocell virus pp65 protein vaccine

Abstract

A human cytomegalovirus pp65 protein vaccine for preventing and blocking primary HCMV infection is prepared through extracting HCMV DNA, amplifying it to obtain the gene fragment pp65(1006-152 / nt), cloning it to the prokaryotic expression carrier PET100-TOPO, exogenous target gene expression in E.coli BL21 cell, extracting target fragment protein pp65, and purifying.

Description

technical field [0001] The invention relates to a protein biological preparation, which is a vaccine for preventing maternal primary or activated human cytomegalovirus (HCMV) infection and blocking HCMV vertical transmission. Background technique [0002] Human Cytomeglalovirus (Human Cytomeglalovirus) HCMV is a double-stranded DNA virus of the herpesvirus β subfamily. CMV infection is very widespread in the population. The initial infection is usually recessive. A few have clinical symptoms. 60-90% of adults have CMV antibodies However, although most people produce specific antibodies after infection, the virus has not been cleared from the human body and has become a latent infection for a long time. In pregnant women with primary or activated HCMV infection, intrauterine infection may even lead to sequelae such as miscarriage, fetal malformation, and deafness and blindness left over from brain and nervous system damage. Congenital HCMV infection mainly comes from the ver...

AI Technical Summary

Problems solved by technology

[0003] In recent years, two live attenuated HCMV vaccines (AD169 and Townel 125) developed abroad have been tested in healthy volunteers and organ transplant recipients. Possibly, later some scholars extracted HCMV subunit peptides as antigens for animal experiments and human experiments, and found that the vaccine stimulated the body and induced neutralizing antibodies were very limited in both quantity and time, and the extraction process was complex and expensive